KOL Insight

Non-Small Cell Lung Cancer KOL Interview – NH, US

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Key Questions in Immuno-Oncology

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

Leukemia KOL Insight and Pulse Survey Bundle

The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.

September 8, 2017

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

2015 Cancer Drug Pricing Surveys

$799.00

We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.

August 10, 2015

Crohn’s Disease KOL Interview – US, South

This discussion with a US-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the latest approved agents in Crohn’s disease, along with the treatment approach in fistulizing Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.

October 14, 2022

Crohn’s Disease KOL Interview – US, Northeast

This discussion with a US-based key opinion leader (KOL) includes in-depth opinions on many topics in the Crohn’s disease market. In the discussion, the KOL addresses what the future of the Crohn’s disease market will look like. Also discussed are competition in the market, and how certain factors will lead to one agent triumphing over another. Additionally, the discussion covers the significance of black box warnings, as well as the latest approved agent in Crohn’s disease.

October 13, 2022

Crohn’s Disease KOL Interview – UK

This discussion with a UK-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the long-term use of biologics and combinations in Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.

October 13, 2022

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for NSCLC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include TIGIT inhibitors, monalizumab, oleclumab, Rybrevant, and repotrectinib.

October 18, 2022

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – Germany

This interview with a Germany-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for NSCLC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include TIGIT inhibitors, monalizumab, oleclumab, Rybrevant, and repotrectinib.

October 17, 2022

Parkinson’s Disease KOL Interview – Italy

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key branded Parkinson’s disease drugs, unmet needs, and promising pipeline candidates and how they compare to one another.

October 10, 2022

Parkinson’s Disease KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key branded Parkinson’s disease drugs and how they are used, and views on promising novel drug targets and late-phase pipeline candidates.

October 10, 2022

Parkinson’s Disease KOL Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key branded drugs in the Parkinson’s disease market and which situations these are used in, promising late-phase pipeline candidates, and the reimbursement issues faced by physicians.

October 10, 2022